Current bone mineral density data on bisphosphonates in postmenopausal osteoporosis

Area of Science:

• Bone biology and pharmacology
• Endocrinology and metabolic diseases
• Geriatric medicine

Background:

• Osteoporosis is a skeletal fragility disorder marked by excessive bone resorption over formation.
• Accelerated bone resorption drives postmenopausal and age-related bone loss, increasing fracture risk.
• Increased bone turnover is an independent risk factor for fractures, irrespective of bone mineral density.

Purpose of the Study:

• To evaluate bisphosphonates as antiresorptive agents for treating postmenopausal osteoporosis.
• To assess the efficacy of bisphosphonates in suppressing bone turnover and improving bone mass.
• To determine the safety and fracture reduction capabilities of bisphosphonates.

Main Methods:

• Review of recent studies involving etidronate, pamidronate, and alendronate.
• Analysis of large-scale and long-term clinical trials with bisphosphonates.
• Assessment of fracture occurrence data in patients treated with bisphosphonates.

Main Results:

• Bisphosphonates demonstrated the ability to suppress bone turnover and preserve or increase bone mass.
• Studies showed decreased fracture occurrence with alendronate, clodronate, and etidronate.
• Bisphosphonates were generally well-tolerated, with upper gastrointestinal intolerance as a noted side effect.

Conclusions:

• Bisphosphonates are effective antiresorptive drugs for postmenopausal osteoporosis, offering an alternative to estrogen.
• These agents reduce fracture risk and are suitable for patients with decreased bone mass, especially severe osteoporosis.
• Further research is needed on optimal dosing, alternative administration routes, combination therapies, and long-term safety.